A Japanese healthcare conglomerate is the lead investor ReCor Medical’s $15 million Series D round ReCor plans to use to back a U.S. clinical trial of its ultrasound renal denervation device.
Otsuka Holdings (TYO:4578) was joined by Sofinnova Partners in the round. ReCor said it’s met with the FDA to discuss its plans for the study of its Paradise RDN system, which would be undertaken at 20 to 25 clinical sites in the U.S. and Europe.
Help employers find you! Check out all the jobs and post your resume.
